The United States Food and Drug Administration shared in a press release that it has approved Pfizer Inc.'s vaccine, Abrysvo, for pregnant individuals that can prevent Respiratory Syncytial Virus in infants, "from birth through 6 months of age."
During a clinical study, it was shown that "among approximately 3,500 pregnant individuals who received Abrysvo, compared to approximately 3,500 pregnant individuals who received placebo, Abrysvo reduced the risk of severe LRTD [lower respiratory tract disease] by 81.8% within 90 days after birth, and 69.4% within 180 days after birth," FDA said.
The FDA mentioned that the most common side effects of taking the vaccine were "pain at the injection site, headache, muscle pain and nausea."
